… of use of valacyclovir for those pregnant women in whom timing of CMV infection can be
adequately assessed, especially given its safety profile relative to ganciclovir or valganciclovir. …

… During the last 2 decades of using ganciclovir or valganciclovir prophylaxis, CMV disease
has been reduced to less than 15%, following solid organ transplants, applied to seropositive …

… to intravenous ganciclovir at … CMV disease with CMV enterocolitis, which was confirmed by
histopathologic analysis. After 2 weeks of treatment with ganciclovir, the patient’s serum CMV …

… While a case series exists describing letermovir in combination with both foscarnet and
high dose IV ganciclovir for resistant/refractory CMV in lung and hematopoetic stem cell …

… the following criteria: positive CMV DNA PCR plus evidence … CMV disease even after
neonatal period in infancy, chorioretinitis and critically ill preterm infants with life-threatening CMV …

… Citation3 The oral prodrug valganciclovir and intravenous ganciclovir are the most common
antiviral agents used for prevention and treatment. Although generally well tolerated, side …

… who developed breakthrough CMV disease while on appropriately dosed oral valganciclovir
prophylaxis, one was due to genotypically proven ganciclovir-resistant CMV, another was a …

… in disease epidemiology with the introduction of antiviral prophylaxis, with CMV disease …
We describe two cases of very late-onset CMV disease where first disease occurred 15 and 18 …

… [11] also found variable CMV DNAemia clearance in patients with appropriate plasma
levels with VGCV therapy for CMV disease in donor-positive/recipient-negative SOT recipients. …

… children with CMV disease in this case. IV ganciclovir, IV foscarnet, IV cidofovir and oral
valganciclovir are choices of antiviral available for CMV retinitis in both adults and children. …